by Megan Brown | Aug 19, 2019 | Uncategorized
Researchers at Washington University School of Medicine in St. Louis, MO recently reported a game changing blood test that could significantly decrease the cost of clinical trials for Alzheimer’s disease. The findings, published August 1st in the journal Neurology,...
by PEPID Newsroom | Jul 23, 2019 | Alerts
A data analysis of 9 studies from 7 publications totaling to 307, 099 participants with 23,544 cases of incident type 2 diabetes showed a significant inverse association between people who adhered to a plant-based dietary pattern and risk of type 2 diabetes compared...
by PEPID Newsroom | Jun 4, 2019 | Alerts
Emgality (gacanezumab-gnlm) solution has been FDA approved for treatment of episodic cluster headache in adults, the first of its kind. Emgality was approved in 2018 to prevent migraines in adults, and now has shown to reduce the frequency of cluster headache attaches...
by PEPID Newsroom | May 24, 2019 | Alerts
Pigray (alpelisib) tablets have been FDA approved to treat breast cancer in combination with FDA-approved endocrine therapy fulvestrant. Pigray is approved for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
by PEPID Newsroom | May 23, 2019 | Alerts, Pharmacy
Every year, the US FDA’s Center for Drug Evaluation and Research (CDER) releases a list of newly-approved novel drugs and therapeutic biological products. Last year’s Novel Drug Approvals list holds the record for the most number of approved drugs, effectively...
by PEPID Newsroom | May 20, 2019 | Alerts
The American Stroke Association released improved recommendations for stroke systems of care to improve patient outcomes. It aims to extensively review of the current evidence evaluating these systems, and provide updates for policymakers and public healthcare...
by Anna Tan | May 2, 2019 | Nursing
Nurses Have it Rough While a 3-day weekly work schedule and constant hiring demand may sound like a dream, many nurses wage a constant battle against burnout. A 2017 survey of over 600 American nurses between the ages of 25 and 55 revealed 50% have considered leaving...
by Anna Tan | Apr 18, 2019 | Uncategorized
Using Critical Appraisal to Find the Best Resources in the Midst of ‘Information Overload’ The rise of evidence-based practice (EBP) has been transformative in accomplishing value-based provider goals and improving patient outcomes. Over 12,000 new...
by PEPID Newsroom | Apr 4, 2019 | Alerts
The FDA is investigating reports of seizures following the use of e-cigarettes, most involving youth and young adult users. The FDA foresees a potential emerging safety issue with the recent voluntary reports of adverse experiences with tobacco products that...
by PEPID Newsroom | Mar 29, 2019 | Alerts
Jatenzo, (testosterone undecanoate) has been given the FDA greenlight to be used as an oral capsule treatment for men with certain forms of hypogonadism. Jatenzo is the first treatment option for men with certain hypogonadal conditions that has an oral route of...
by PEPID Newsroom | Feb 13, 2019 | Emergency Medicine, Nursing, Pharmacy, Primary Care
Founder and CEO, Mark Rosenbloom, MD, MBA joins PEPID Pulse’s Implementing Precision Medicine live broadcast series at HIMSS 2019. Dr. Rosenbloom’s talk, “Implementing Precision Medicine in the Clinical Setting: Challenges and Rewards” expounds on: Pharmacogenomics’...
by PEPID Newsroom | Feb 13, 2019 | Emergency Medicine, Featured Posts, Nursing, Pharmacy, Primary Care
PEPID’s Executive Vice President and Chief Technology Officer, Edward Reynolds joins the Pulse during HIMSS 2019 to talk about the development strategy and objectives behind the company’s most cutting-edge release. His talk, “Precision without Fatigue: Focusing on...
by PEPID Newsroom | Jan 7, 2019 | Press & Media
January 7, 2019 — Phoenix, AZ — Trusted medical information and point-of-care solutions provider, PEPID, LLC is pleased to announce another partnered advance towards patient-centered care. Moving forward with PEPID’s Bedside Education is Florida State University’s...
by Megan Brown | Jan 2, 2019 | Alerts
The injection Ultomirus (ravulizumab) has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is a long-acting complement inhibitor that prevents hemolysis. Richard Pazdur, M.D., director of the FDA’s Oncology...
by Anna Tan | Nov 28, 2018 | Featured Posts
Healthcare reform and improvement has entered exciting times. Medical R&D and health informatics (HIT) are growing at a rapid rate, offering better options to a more curious and proactive generation of consumers. More regulatory bodies and forward-thinking...
